ZymoGenetics' Biotech Disconnect
Executive Summary
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.
You may also be interested in...
Novo-ZymoGenetics: The Next Roche-Genentech?
Novo Nordisk's decision to spin off ZymoGenetics in 2000 was 100% inspired by Roche's hands-off relationship with Genentech. The parent claims Zymo's R&D productivity has since increased; its recent ex-US deal with Bayer-Schering on recombinant thrombin proves that Zymo has certainly grown up and left home.
Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono
The broad research, development and commercialization alliance inked in September between ZymoGenetics Inc. and Serono SA stands out not only for its size and scope--an unlimited number of proteins and up-front equity purchases and license fees totalling $81.25 million--but also because each partner is a biotech company, and the research chores will be shared from the outset.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.